Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
October 2012

Lurasidone (Latuda) in Context
The new antipsychotic lurasidone (Latuda) may cause less weight gain than other second-generation antipsychotics but may not be the most efficacious treatment for patients with schizophrenia.

Antidepressants and Acute Angle-Closure Glaucoma
Recent use of antidepressants appears to increase the risk of acute angle-closure glaucoma in elderly patients.

Clozapine Can Prevent Suicide
An increased use of clozapine (Clozaril and others) to treat schizophrenia would prevent more suicides than the number of deaths that would be caused by its adverse events.

In Brief
Obesity and Metabolic Abnormalities in Midlife Associated with Later Cognitive Decline; EMR Practices Provide Less Depression Treatment for Patients with More Complex Conditions

Doctors Overestimate Patient Adherence to Antipsychotics
In a recent survey, physicians were correct about the level of treatment adherence for only about half of their patients.

Osteoporosis, Fracture Risk, and Schizophrenia
Data suggest that both schizophrenia and the drugs used to treat it increase the risk of fractures by causing osteoporosis.

Lurasidone (Latuda) in Context

October 2012

With funding from Sunovion Pharmaceuticals, the manufacturer of the new antipsychotic lurasidone (Latuda), Citrome analyzed pooled data from studies conducted before this agent was approved for clinical use.1 The studies were 6-week, randomized, placebo-controlled trials of lurasidone,…

To view the rest of this article, please: